Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeoImmuneTech, Inc.

http://neoimmunetech.com/

Latest From NeoImmuneTech, Inc.

Coronavirus Update: GSK Stresses Need For Broad Vaccines Amid Future Pandemic Risk

Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.

Coronavirus COVID-19 Companies

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Deals Coronavirus COVID-19

Cellid IPO To Fund First-In-Class Cancer Immunotherapeutic Vaccines

After using government financial support to fund its early-stage clinical trials, Korean bioventure Cellid aims to further progress its first-in-class, cell-based cancer immunotherapeutic vaccines through an initial public offering in February.

South Korea Financing

Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC

Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.

Asia Pacific Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
UsernamePublicRestriction

Register